Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rapoport

Showing results (101-110 of 179) with videos related to

Pageof 18
Sort By:
Blood Cells, Molecules & Diseases|August 3, 2001
Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genesA P Rapoport, M Simons-Evelyn, T Chen, et al.
Cancer|February 2, 2019
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2James K Godfrey, Chadi Nabhan, Theodore Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.
Bone Marrow Transplantation|April 1, 1995
Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 yearsA P Rapoport, J F DiPersio, B A Martin, et al.
Bone Marrow Transplantation|February 2, 2016
Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantationJ A Yared, N Hardy, Z Singh, et al.
Cancer|December 4, 2014
Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center studyVishal Bhatnagar, Yin Wu, Olga G Goloubeva, et al.
Journal for Immunotherapy of Cancer|July 19, 2022
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccineDjordje Atanackovic, Robert J Kreitman, Jeffrey Cohen, et al.
Bone Marrow Transplantation|June 17, 2018
Final outcomes of escalated melphalan 280 mg/m<sup>2</sup> with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survivalParameswaran Hari, Donna E Reece, Jasleen Randhawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2009
Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapyMerry Y Zhao, Aaron Auerbach, Anisha M D'Costa, et al.
American Journal of Hematology|July 26, 2019
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen lossAli Bukhari, Firas El Chaer, Rima Koka, et al.
Pageof 18

Showing results (101-110 of 179) with videos related to

Sort By:
Pageof 18
Blood Cells, Molecules & Diseases|August 3, 2001
Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genesA P Rapoport, M Simons-Evelyn, T Chen, et al.
Cancer|February 2, 2019
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2James K Godfrey, Chadi Nabhan, Theodore Karrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patientsNaoko Takebe, Xiangfei Cheng, Suhlan Wu, et al.
Bone Marrow Transplantation|April 1, 1995
Patients > or = age 40 years undergoing autologous or allogeneic BMT have regimen-related mortality rates and event-free survivals comparable to patients < age 40 yearsA P Rapoport, J F DiPersio, B A Martin, et al.
Bone Marrow Transplantation|February 2, 2016
Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantationJ A Yared, N Hardy, Z Singh, et al.
Cancer|December 4, 2014
Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center studyVishal Bhatnagar, Yin Wu, Olga G Goloubeva, et al.
Journal for Immunotherapy of Cancer|July 19, 2022
T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccineDjordje Atanackovic, Robert J Kreitman, Jeffrey Cohen, et al.
Bone Marrow Transplantation|June 17, 2018
Final outcomes of escalated melphalan 280 mg/m<sup>2</sup> with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survivalParameswaran Hari, Donna E Reece, Jasleen Randhawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2009
Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapyMerry Y Zhao, Aaron Auerbach, Anisha M D'Costa, et al.
American Journal of Hematology|July 26, 2019
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen lossAli Bukhari, Firas El Chaer, Rima Koka, et al.
Pageof 18